Evan/ Fa Jones Sells 20,000 Shares of Veracyte, Inc. (VCYT) Stock
Veracyte, Inc. (NASDAQ:VCYT) Director Evan/ Fa Jones sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $7.92, for a total value of $158,400.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Evan/ Fa Jones also recently made the following trade(s):
- On Thursday, August 24th, Evan/ Fa Jones sold 40,000 shares of Veracyte stock. The stock was sold at an average price of $7.88, for a total value of $315,200.00.
Shares of Veracyte, Inc. (VCYT) opened at 7.87 on Friday. The firm’s market cap is $266.74 million. Veracyte, Inc. has a 52-week low of $5.34 and a 52-week high of $9.71. The stock’s 50 day moving average price is $8.07 and its 200-day moving average price is $8.24.
Veracyte (NASDAQ:VCYT) last posted its quarterly earnings data on Monday, July 31st. The biotechnology company reported ($0.22) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.03. The business had revenue of $18.40 million for the quarter, compared to analysts’ expectations of $18.32 million. Veracyte had a negative return on equity of 53.58% and a negative net margin of 35.64%. The business’s revenue was up 25.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.40) EPS. On average, analysts forecast that Veracyte, Inc. will post ($0.93) EPS for the current year.
A number of equities research analysts have recently commented on the company. BidaskClub raised Veracyte from a “sell” rating to a “hold” rating in a research report on Monday, July 31st. Janney Montgomery Scott reaffirmed a “buy” rating and set a $15.00 price target on shares of Veracyte in a research report on Wednesday, June 28th. Cantor Fitzgerald set a $13.00 price target on Veracyte and gave the stock a “buy” rating in a research report on Thursday, May 18th. Finally, Zacks Investment Research raised Veracyte from a “hold” rating to a “buy” rating and set a $9.25 price target on the stock in a research report on Friday, August 4th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $12.25.
A number of hedge funds have recently bought and sold shares of VCYT. Bank of Montreal Can purchased a new stake in Veracyte during the first quarter valued at $138,000. Boston Advisors LLC purchased a new stake in Veracyte during the first quarter valued at $445,000. Nationwide Fund Advisors boosted its stake in Veracyte by 31.9% in the first quarter. Nationwide Fund Advisors now owns 11,327 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 2,739 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in Veracyte during the first quarter valued at $147,000. Finally, Wells Fargo & Company MN boosted its stake in Veracyte by 112.8% in the first quarter. Wells Fargo & Company MN now owns 18,752 shares of the biotechnology company’s stock valued at $172,000 after buying an additional 9,938 shares during the last quarter. 63.57% of the stock is currently owned by institutional investors and hedge funds.
Veracyte, Inc is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.
Receive News & Ratings for Veracyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.